Homepage
Author:
Moderna, Inc.
Posted Date:
March 3, 2026
Moderna Resolves Global Patent Litigation with Arbutus/Genevant
Moderna, Inc.
March 3, 2026
European Medicines Agency’s Committee for Medicinal Products for Human Use Adopts Positive Opinion Recommending Marketing Authorization of mCOMBRIAX, Moderna’s mRNA Combination Vaccine Against Influenza and COVID-19
Moderna, Inc.
February 27, 2026
Moderna to Present at Upcoming Conferences in March 2026
Moderna, Inc.
February 19, 2026
Moderna Announces the U.S. Food and Drug Administration will Initiate the Review of Its Investigational Seasonal Influenza Vaccine Submission
Moderna, Inc.
February 18, 2026
Moderna Receives European Commission Marketing Authorization for COVID-19 Vaccine mNEXSPIKE
Moderna, Inc.
February 17, 2026
Moderna Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Business Updates
Moderna, Inc.
February 13, 2026
Moderna Receives Refusal-to-File Letter from the U.S. Food and Drug Administration for Its Investigational Seasonal Influenza Vaccine, mRNA-1010
Moderna, Inc.
February 10, 2026
Moderna to Enter into Long-Term Strategic Agreement with the Government of Mexico
Moderna, Inc.
February 10, 2026
Dr. David Berman to Join Moderna as Chief Development Officer
Moderna, Inc.
January 30, 2026
Moderna Announces Strategic Collaboration with Recordati to Globally Commercialize Investigational Propionic Acidemia Therapeutic (mRNA-3927)
Moderna, Inc.
January 29, 2026
1
2
Next
